-
Cidara Therapeutics NASDAQ:CDTX Cidara Therapeutics Inc. isa is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California.
Location: 6310 Nancy Ridge Dr Ste 101, California, 92121-3209, US | Website: www.cidara.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-79.97M
Cash
164.4M
Avg Qtr Burn
-31.2M
Short % of Float
1.99%
Insider Ownership
4.73%
Institutional Own.
52.11%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
REZZAYO (Rezafungin) Details Infectious disease, Fungal infections, Candidemia | Approved Quarterly sales | |
Rezafungin Details Infectious disease, Fungal infections | Phase 3 Update | |
CD388 (DFCs) Details Infectious disease, Influenza | Phase 2b Data readout |